TY - JOUR
AU1 - Waters, Aoife
AB - Pediatr Nephrol (2011) 26:1917–1918 DOI 10.1007/s00467-011-1930-x LETTER TO THE EDITORS Optimizing treatment strategies in paediatric atypical hemolytic uremic syndrome Aoife Waters Received: 21 April 2011 /Accepted: 21 April 2011 /Published online: 7 June 2011 IPNA 2011 Dear Sirs, both, whether volume replacement in the context of PEX The letter by Davin and colleagues in this issue of Pediatric consisted of albumin or fresh frozen plasma (FFP) and, Nephrology on the long-term efficacy of plasma therapy finally, the duration and frequency involved. PEX is (PT) in atypical haemolytic uraemic syndrome (aHUS) is favoured as the initial modality of choice as it allows the timely with the advent of an open-label, multi-centre delivery of higher quantities of FFP (up to 40–60 ml/kg per clinical trial addressing the role of eculizumab in paediatric session) whilst avoiding hypervolaemia with consequent aHUS [1]. Almost 15 years have passed since a genetic hypertension, cardiac failure and hyperproteinaemia than if locus for familial aHUS was mapped to the RCA gene PI were administered three times weekly at 10–20 ml/kg cluster at chromosome 1q32. Mutations in complement per session. While guidelines have recently been proposed pathway components now account for about 60% of aHUS for the initial 
TI - Optimizing treatment strategies in paediatric atypical hemolytic uremic syndrome
JF - Pediatric Nephrology
DO - 10.1007/s00467-011-1930-x
DA - 2011-06-07
UR - https://www.deepdyve.com/lp/springer-journals/optimizing-treatment-strategies-in-paediatric-atypical-hemolytic-lJuqkjTPwm
SP - 1917
EP - 1918
VL - 26
IS - 10
DP - DeepDyve
ER -